EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
EyePoint Pharmaceuticals Inc
Cash & Cash Equivalents
EyePoint Pharmaceuticals Inc
Cash & Cash Equivalents Peer Comparison
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
|
Cash & Cash Equivalents
$271m
|
CAGR 3-Years
25%
|
CAGR 5-Years
44%
|
CAGR 10-Years
31%
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash & Cash Equivalents
$7.2B
|
CAGR 3-Years
19%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-10%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash & Cash Equivalents
$9.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
Pfizer Inc
NYSE:PFE
|
Cash & Cash Equivalents
$719m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-13%
|
|
Merck & Co Inc
NYSE:MRK
|
Cash & Cash Equivalents
$5.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-10%
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash & Cash Equivalents
$2.5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-4%
|
See Also
What is EyePoint Pharmaceuticals Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
271m
USD
Based on the financial report for Mar 31, 2024, EyePoint Pharmaceuticals Inc's Cash & Cash Equivalents amounts to 271m USD.
What is EyePoint Pharmaceuticals Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
31%
Over the last year, the Cash & Cash Equivalents growth was 156%. The average annual Cash & Cash Equivalents growth rates for EyePoint Pharmaceuticals Inc have been 25% over the past three years , 44% over the past five years , and 31% over the past ten years .